Study finds mixed results in relationship between pazopanib exposure and liver toxicity

A retrospective observational cohort study did not find a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity in real-world patients. While liver toxicity was observed in 19% of the patients, the analysis of pazopanib exposure did not show a significant difference between patients with and without liver toxicity.

Additionally, the study revealed that, despite the occurrence of liver toxicity, successful interventions in routine clinical care allowed half of the affected patients to safely continue or restart pazopanib treatment at the same dose as before the onset of liver toxicity. This led to the development of an algorithm for the management of pazopanib-induced liver toxicity, providing potential guidance for healthcare professionals in optimizing treatment outcomes for patients undergoing pazopanib therapy.

Reference
Westerdijk K, Krens SD, Steeghs N, et al. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemother Pharmacol. 2023;doi: 10.1007/s00280-023-04615-7. Epub ahead of print. PMID: 38104304.